Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a0c93e212918cf2d2fa9e3ae8c4706a7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7a91092f32dae07c7e18f5a6cc1986ee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_38ddf07b15d338a1f8f184ec80db6ab0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cbc5b09bb0acf1d76a969b7f38f90351 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5152 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55516 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 |
filingDate |
2011-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae33088ea05a55d4f3514502d5618790 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4fc429ab4e3cfdb25bf8995f9e7a2979 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f56714020c40b6599099aeb405da2980 |
publicationDate |
2013-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2013309267-A1 |
titleOfInvention |
Cancer immunotherapy compositions and methods of use |
abstract |
Cellular compositions and methods for inducing an immune response to tumor cells are described. The cellular compositions include a tumor antigen and cells that have been modified to express a cytokine and one or more of a tumor antigen, anti-CTLA4 antibody and an additional cytokine. The cellular compositions find utility in methods for treating cancer. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11649288-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017044487-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11311576-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11571463-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11759480-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11779602-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10525082-B2 |
priorityDate |
2006-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |